GlassScriptPhysician profile
Kourosh Shargani
NPI 1700347556
$8,217.00
in general payments reported to CMS, 2019-2025
23 companies · $5,809 in 2025
The $5,809 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,408 · 2025: $5,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,955 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,954.68 |
| Education | $262.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,064.34 | 2024-2025 | Tavneos, Evenity, Otezla |
| Janssen Biotech, INC. | $1,351.20 | 2024-2025 | Tremfya, Simponi Aria |
| Abbvie INC. | $1,263.86 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $796.72 | 2024-2025 | Acthar |
| Ucb, INC. | $470.19 | 2024-2025 | Bimzelx, Cimzia |
| Sobi, INC | $271.83 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $248.66 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $200.10 | 2024-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.84 | 2025 | Ofev |
| Pfizer INC. | $163.42 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $158.29 | 2024-2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $157.27 | 2024 | Arcalyst |
| Celltrion USA INC. | $146.92 | 2025 | Zymfentra |
| Lilly USA, LLC | $144.83 | 2024-2025 | Taltz |
| Octapharma USA, INC. | $117.22 | 2024-2025 | Octagam Immune Globulin (Human), Panzyga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $109.19 | 2025 | Tremfya |
| Genentech USA, INC. | $106.16 | 2024-2025 | Actemra |
| Alexion Pharmaceuticals, INC. | $77.18 | 2024-2025 | Strensiq |
| Radius Health, INC. | $72.56 | 2024-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $43.68 | 2024-2025 | Orencia |
| Sun Pharmaceutical Industries INC. | $31.33 | 2025 | |
| Bioventus LLC | $23.17 | 2024 | Durolane |
| Grifols USA, LLC | $21.04 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kourosh Shargani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.